
Richard Alan Bender MD FACP
Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology
Senior Consultant for Medical Affairs, Quest Diagnostics San Juan Capistrano, CA
Join to View Full Profile
26732 Crown Valley Pkwy Ste 271Mission Viejo, CA 92691
Phone+1 949-427-7933
Fax+1 949-715-1273
Dr. Bender is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1970 - 1972
- David Geffen School of Medicine at UCLAClass of 1970
- University of California, Santa BarbaraB.A., Biology, With High Honors, 1966
- University of California, Santa BarbaraBA, Biology, with High Honors, 1966
Certifications & Licensure
- CA State Medical License 1971 - 2026
- AZ State Medical License 2005 - 2022
- NE State Medical License 2005 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Medical Intern of the Year 1971
- Regents Scholar State of California, 1966
- Alpha Omega Alpha Medical Honor Society
- Join now to see all
Publications & Presentations
PubMed
- 43 citationsMolecular Classification of Unknown Primary CancerRichard A. Bender, Mark G. Erlander
Seminars in Oncology. 2009-02-01 - 48 citationsDistribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.J. Liu, Kevin Qu, Anthony Sferruzza, Richard A. Bender
Anti-Cancer Drugs. 2007-07-01 - 187 citationsThe HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast CancerXiao-Jun Ma, Susan G. Hilsenbeck, Wilson Wang, Li Ding, Dennis C. Sgroi
Journal of Clinical Oncology. 2006-10-01
Journal Articles
- "Molecular Identification of Carcinoma of Unknown Primary (CUP) with Gene Expression Profiling"Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
- "Preliminary Study of Three Tumor Markers for Hepatocellular Carcinoma: AFP, AFP-L3 and Glypican-3"Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
- "A Multiplex Assay for Detection of Common Pediatric Sarcoma Tumor Markers"Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
- Join now to see all
Abstracts/Posters
- Personalized Treatment of Advanced Metastatic Breast Cancer (MBC) Utilizing Target Now in a Community- Based Oncology PracticeLoesch D, Waisman J, Link J, Alarcon A, Boehm K, Ghazadpour A and Bender R,, San Antonio Breast Cancer Symposium, 12/7/2011
- Differences in gene expression between primary chemotherapy-naïve prostate carcinomas and hormone-refractory prostate carcinomasBasu G, McGinniss M, Alarcon A, Kemkes A and Bender R, ASCO-EORTC conference, San Francisco, 11/16/2011
- Differences in gene expression between primary chemotherapy-naive prostate carcinomas and hormone-refractory prostate carcinomasBasu G, McGinniss M, Alarcon A, Kemkes A and Bender R, ASCO-EORTC conference on “Molecular Targets and Cancer Therapeutics", 11/12/2011
- Join now to see all
Press Mentions
- Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual MeetingDecember 8th, 2022
- Telo Genomics Engages Key Opinion Leader to Form and Chair Myeloma Advisory BoardOctober 18th, 2022
- Presentations at French Society of Plastic, Reconstructive and Aesthetic Surgery Reinforce Benefits of ReCell(R)November 29th, 2016
- Join now to see all
Professional Memberships
- Member
- Fellow
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: